Receptor tyrosine kinase inhibitors for the treatment of recurrent and unresectable bone sarcomas
V Albarrán, ML Villamayor, J Chamorro… - International Journal of …, 2022 - mdpi.com
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …
Receptor tyrosine kinases in osteosarcoma treatment: which is the key target?
Z Tian, X Niu, W Yao - Frontiers in Oncology, 2020 - frontiersin.org
Recent clinical trials have shown several multi-target tyrosine kinase inhibitors (TKIs) to be
effective in the treatment of osteosarcoma. However, these TKIs have a number of targets …
effective in the treatment of osteosarcoma. However, these TKIs have a number of targets …
[HTML][HTML] Tyrosine Kinase Inhibitors in Osteosarcoma: Adapting Treatment Strategies
A Assi, M Farhat, MCR Hachem, Z Zalaquett… - Journal of Bone …, 2023 - Elsevier
Osteosarcoma (OS) is an aggressive primary bone malignancy that metastasizes rapidly.
The standard of care has changed little over the previous four decades, and survival rates …
The standard of care has changed little over the previous four decades, and survival rates …
Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
EDG Fleuren, YMH Versleijen-Jonkers… - … et Biophysica Acta (BBA …, 2014 - Elsevier
Osteosarcoma (OS) and Ewing sarcoma (ES) are the two most common types of primary
bone cancer, which mainly affect children and young adults. Despite intensive multi-modal …
bone cancer, which mainly affect children and young adults. Despite intensive multi-modal …
Targeted therapies in bone sarcomas: current approach and future directions
JL Yarber, M Agulnik - Expert Opinion on Investigational Drugs, 2011 - Taylor & Francis
Introduction: Bone sarcomas are rare malignancies and once advanced, there is limited
response to current chemotherapeutic regimens. Targeted therapies could have substantial …
response to current chemotherapeutic regimens. Targeted therapies could have substantial …
Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
C Chen, Q Shi, J Xu, T Ren, Y Huang, W Guo - Cell Death Discovery, 2022 - nature.com
Osteosarcoma (OS) is a mesenchymal-origin tumor that constitutes the most common
primary malignant bone tumor. The survival rate of the patients has significantly improved …
primary malignant bone tumor. The survival rate of the patients has significantly improved …
Current molecular targeted therapies for bone and soft tissue sarcomas
K Nakano, S Takahashi - International journal of molecular sciences, 2018 - mdpi.com
Systemic treatment options for bone and soft tissue sarcomas remained unchanged until the
2000s. These cancers presented challenges in new drug development partly because of …
2000s. These cancers presented challenges in new drug development partly because of …
Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
Z Liu, S Gao, L Zhu, J Wang, P Zhang, P Li… - Cancer …, 2021 - Wiley Online Library
Abstract Background Tyrosine kinase inhibitors (TKIs) such as cabozantinib, regorafenib
have demonstrated encouraging activity in prolonging progression‐free survival (PFS) in …
have demonstrated encouraging activity in prolonging progression‐free survival (PFS) in …
Bone sarcomas: from biology to targeted therapies
N Gaspar, A Di Giannatale, B Geoerger, F Redini… - Sarcoma, 2012 - Wiley Online Library
Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases
which occur mainly in adolescents and young adults. With the current therapies, some …
which occur mainly in adolescents and young adults. With the current therapies, some …
Receptor tyrosine kinases in osteosarcoma: 2019 update
EM Greenfield, CD Collier, PJ Getty - Current advances in the science of …, 2020 - Springer
The primary conclusions of our 2014 contribution to this series were as follows: Multiple
receptor tyrosine kinases (RTKs) likely contribute to aggressive phenotypes in …
receptor tyrosine kinases (RTKs) likely contribute to aggressive phenotypes in …